Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Experimental Pediatric Endocrinology, Berlin, Germany.
Institute of Anatomy, University of Leipzig, Leipzig, Germany.
Thyroid. 2020 Sep;30(9):1366-1383. doi: 10.1089/thy.2019.0544. Epub 2020 Apr 17.
Mutations of monocarboxylate transporter 8 (MCT8), a thyroid hormone (TH)-specific transmembrane transporter, cause a severe neurodevelopmental disorder, the Allan-Herndon-Dudley syndrome. In MCT8 deficiency, TH is not able to reach those areas of the brain where TH uptake depends on MCT8. Currently, therapeutic options for MCT8-deficient patients are missing, as TH treatment is not successful in improving neurological deficits. Available data on MCT8 protein and transcript levels indicate complex expression patterns in neural tissue depending on species, brain region, sex, and age. However, information on human MCT8 expression is still scattered and additional efforts are needed to map sites of MCT8 expression in neurovascular units and neural tissue. This is of importance because new therapeutic strategies for this disease are urgently needed. To identify regions and time windows of MCT8 expression, we used highly specific antibodies against MCT8 to perform immunofluorescence labeling of postnatal murine brains, adult human brain tissue, and human cerebral organoids. Qualitative and quantitative analyses of murine brain samples revealed stable levels of MCT8 protein expression in endothelial cells of the bloodbrain barrier (BBB), choroid plexus epithelial cells, and tanycytes during postnatal development. Conversely, the neuronal MCT8 protein expression that was robustly detectable in specific brain regions of young mice strongly declined with age. Similarly, MCT8 immunoreactivity in adult human brain tissue was largely confined to endothelial cells of the BBB. Recently, cerebral organoids emerged as promising models of human neural development and our first analyses of forebrain-like organoids revealed MCT8 expression in early neuronal progenitor cell populations. With respect to MCT8-deficient conditions, our analyses not only strongly support the contention that the BBB presents a lifelong barrier to TH uptake but also highlight the need to decipher the TH transport role of MCT8 in early neuronal cell populations in more detail. Improving the understanding of the spatiotemporal expression in latter barriers will be critical for therapeutic strategies addressing MCT8 deficiency in the future.
单羧酸转运蛋白 8(MCT8)是甲状腺激素(TH)特异性跨膜转运蛋白,其突变会导致严重的神经发育障碍,即 Allan-Herndon-Dudley 综合征。在 MCT8 缺乏的情况下,TH 无法到达那些依赖 MCT8 摄取 TH 的大脑区域。目前,MCT8 缺乏患者的治疗选择还不存在,因为 TH 治疗并不能改善神经缺陷。关于 MCT8 蛋白和转录本水平的现有数据表明,在神经组织中,物种、脑区、性别和年龄等因素会导致复杂的表达模式。然而,关于人类 MCT8 表达的信息仍然分散,需要进一步努力来绘制神经血管单元和神经组织中 MCT8 表达的部位。这一点很重要,因为迫切需要为这种疾病开发新的治疗策略。为了确定 MCT8 的表达区域和时间窗口,我们使用针对 MCT8 的高度特异性抗体,对新生鼠脑、成年人大脑组织和人脑类器官进行免疫荧光标记。对鼠脑样本的定性和定量分析表明,MCT8 蛋白在血脑屏障(BBB)的内皮细胞、脉络丛上皮细胞和室管膜细胞中,在出生后发育过程中保持稳定的表达水平。相反,在年轻小鼠的特定脑区中,可强烈检测到的神经元 MCT8 蛋白表达,随着年龄的增长而显著下降。同样,成年人大脑组织中的 MCT8 免疫反应性主要局限于 BBB 的内皮细胞。最近,人脑类器官作为人类神经发育的有前途的模型出现,我们对前脑样类器官的首次分析显示 MCT8 在早期神经元祖细胞群体中表达。就 MCT8 缺乏的情况而言,我们的分析不仅强烈支持 BBB 是 TH 摄取的终身屏障的观点,而且还强调需要更详细地阐明 MCT8 在早期神经元细胞群体中的 TH 转运作用。提高对后者屏障时空表达的理解,对于未来解决 MCT8 缺乏症的治疗策略至关重要。